Jacqueline Dünisch, Labor LS
Dr Anja Fritsch, Confarma
Maria Gajewi, Microcoat
Dr Andreas Karst, Haemochrom Diagnostica
Dr Koen Marijt, MAT Research
Katrin Pauls, Lonza
Stéphanie Richard, Sanofi Pasteur
Dr Ruth Röder, Microcoat
Shabnam Solati, CTL-MAT
Dr Ingo Spreitzer, Paul-Ehrlich-Institut
Dr Sandra Stoppelkamp, Universität Tübingen and South Westphalia University of Applied Sciences
This unique event is organised to gain practical experience in performing the Monocyte Activation Test. Further, it brings together industry and regulatory representatives in order to discuss the practical experiences in using MAT, the advantages, the pitfalls, the available systems as well as the regulatory experiences. The purpose is to provide the participants with guidance and support and hands on laboratory training for the implementation and use of the MAT.
During recent years manifold advances have taken place to replace both, Rabbit Pyrogen Test (RPT) and in some cases the Limulus Amebocyte Lysate Test (LAL).
Some of the reasons are:
- Animal experiments have to be reduced. Especially with the current EU Regulations.
- Reduction of variance by validatable in-vitro test Methods
- Get an alternative Test, where the classic LAL shows some gaps, e.g. Contamination of biologicals by non-endotoxin pyrogens not detectable in LAL test is not unlikely.
True In-vitro Pyrogen Tests (IVPT) have been developed in several European countries (United Kingdom, The Netherlands, Switzerland, Germany) in national and international research projects. The tests imitate the central step of human fever reaction, i.e. the activation of human monocytes by endotoxin as well as non-endotoxin pyrogens. One result of all these activities is the Monocyte Activation Test (MAT).
Following, with continuous support by the German Pharmacopoeia, the EDQM MAT Expert group was re-established and finally the MAT Monograph 2.6.30. was implemented into the European Pharmacopoeia in 2010. Meanwhile, the EDQM performed a MAT-survey to improve the MAT monograph and the BET-Guideline 5.1.10. and the Rabbit Pyrogen Test (RPT) monograph, 2.6.8. have been revised to clarify the priorisation of the MAT compared to the RPT (especially in regards to the EU directive 2010/63). However, there are still open questions how MAT can be applied in a routine lab for release testing. The meeting will give guidance for proper use of MAT and strengths and weaknesses will be discussed.
This course is addressed to all persons of
- pharmaceutical manufacturers
- biopharmaceutical companies
- medical device manufacturers
- contract laboratories
- tissue establishments
who are involved in Endotoxin and Pyrogen Testing in development, IPC or release.
The presentations for this event will be available for you to download and print before and after the event. Please note that no printed materials will be handed out on site and that there will not be any opportunity to print the presentations on site. After the event, you will automatically receive your certificate of participation.
On site, we will implement the necessary and required hygiene measures in close co-operation with the hotel. If infection rates and/or travel restrictions generally do not permit an on-site event, will be postponed or offered live online. In this case, you will be informed in due time.